Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
7.140USD
-0.530-6.91%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
161.81MMarket Cap
LossP/E TTM
More Details of Karyopharm Therapeutics Inc Company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc Info
Ticker SymbolKPTI
Company nameKaryopharm Therapeutics Inc
IPO dateNov 06, 2013
CEOPaulson (Richard A)
Number of employees279
Security typeOrdinary Share
Fiscal year-endNov 06
Address85 Wells Avenue
CityNEWTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02459
Phone16176580600
Websitehttps://karyopharm.com/
Ticker SymbolKPTI
IPO dateNov 06, 2013
CEOPaulson (Richard A)
Company Executives of Karyopharm Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
13.01K
+4.14%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
12.50K
+3.94%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
13.01K
+4.14%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
12.50K
+3.94%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Commodore Capital LP
8.65%
RA Capital Management, LP
8.51%
T. Rowe Price Investment Management, Inc.
6.62%
J. Wood Capital Advisors LLC
3.48%
Vanguard Capital Management, LLC
3.28%
Other
69.47%
Shareholders
Shareholders
Proportion
Commodore Capital LP
8.65%
RA Capital Management, LP
8.51%
T. Rowe Price Investment Management, Inc.
6.62%
J. Wood Capital Advisors LLC
3.48%
Vanguard Capital Management, LLC
3.28%
Other
69.47%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.88%
Investment Advisor
14.61%
Venture Capital
9.19%
Investment Advisor/Hedge Fund
4.42%
Corporation
3.48%
Individual Investor
1.37%
Research Firm
1.02%
Other
35.03%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
236
14.10M
62.56%
+5.06M
2025Q4
232
6.65M
36.30%
+1.14M
2025Q3
251
4.11M
24.14%
-1.36M
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
1.49M
6.62%
-812.83K
-35.28%
Dec 31, 2025
J. Wood Capital Advisors LLC
784.80K
3.48%
+326.67K
+71.30%
Oct 14, 2025
Ikarian Capital LLC
544.55K
2.42%
+517.30K
+1897.85%
Dec 31, 2025
Millennium Management LLC
1.01M
4.47%
+1.01M
--
Feb 04, 2026
Soleus Capital Management, L.P.
440.00K
1.95%
+440.00K
--
Dec 31, 2025
Adage Capital Management, L.P.
421.32K
1.87%
--
--
Dec 31, 2025
Davidson Kempner Capital Management LP
310.02K
1.38%
+310.02K
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
